Compare HOFT & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOFT | UNCY |
|---|---|---|
| Founded | 1924 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 145.3M |
| IPO Year | 1999 | 2021 |
| Metric | HOFT | UNCY |
|---|---|---|
| Price | $13.99 | $4.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 58.3K | ★ 1.9M |
| Earning Date | 04-16-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $278,139,000.00 | $675,000.00 |
| Revenue This Year | $17.37 | N/A |
| Revenue Next Year | $9.00 | $582.86 |
| P/E Ratio | $138.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.62 | $3.72 |
| 52 Week High | $18.09 | $8.74 |
| Indicator | HOFT | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 37.27 |
| Support Level | $11.99 | $4.28 |
| Resistance Level | $15.97 | $5.39 |
| Average True Range (ATR) | 0.80 | 0.30 |
| MACD | -0.15 | 0.03 |
| Stochastic Oscillator | 26.60 | 9.62 |
Hooker Furnishings Corp is a designer, marketer, and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality, and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segments: Hooker Branded segment, Domestic Upholstery segment, and All Other. It generates the majority of its revenue from the Hooker Branded segment.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.